For people who have been newly diagnosed with type 1, Italian researchers suggest that intensive insulin therapy (ITT) coupled with nicotinamide for two years improves metabolic control.
The researchers analyzed data from 25 newly diagnosed type 1 patients with an average age of 14.7 years. Nicotinamide (a form of vitamin B3) at a dose of 25 milligrams per kilogram of body weight was added from time of diagnosis to three injections of regular insulin at meals plus one NPH at bedtime and was continued for up to two years after diagnosis.
“In both nicotinamide and control patients, no decline in C-peptide was detected two years after diagnosis,” write the researchers, “indicating that IIT preserves C-peptide secretion.”
A1C was also significantly lower two years after diagnosis in patients treated with nicotinamide plus ITT. No adverse effects were observed in the patient population.
“We conclude that nicotinamide plus intensive insulin therapy at diagnosis of [type 1 diabetes] prolonged for up to two years can be recommended, but longer follow up is required to determine whether nicotinamide should be continued beyond this period.”
* * *
— Journal of Pediatric Endocrinology and Metabolism, August 18, 2005